Home \ Neurology \ EPICA. A study of the efficacy and safety of Mexidol in stroke treatment

Epica. Study of the effectiveness and safety of Mexidol in the treatment of strokes

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:00
Mexidol® - evidence -based medicine
03:06
The purpose of the study of Epica.
03:20
Criteria for inclusion and research methods.
05:52
Assessment of neurological status and effects of the drug.
07:00
Comparability of groups and analysis features.
07:50
The primary criterion for evaluating effectiveness on the Rankin scale.
10:20
Secondary effectiveness criteria.
10:28
Assessment of the quality of life and the dynamics of changes.
12:36
Reducing the severity of symptoms of depression and cognitive disorders.
13:38
Patient profile and improvement of the quality of life.
14:22
Mexidol® after a stroke - treatment results

Lyudmila Vitalievna Stakhovskaya – Doctor of Medical Sciences, Professor, Director of the Research Institute of Cerebrovascular Pathology and Stroke, Department of Fundamental and Clinical Neurology and Neurosurgery of the N.I. Pirogov Russian National Research Medical University

Announcement:

Mexidol®is a well-known medication with proven efficacy, helping patients return to active life with long-term therapy. The EPICA study of Mexidol® clinically evaluated its efficacy and safety in patients with ischemic stroke.

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:00
Mexidol® - evidence -based medicine
03:06
The purpose of the study of Epica.
03:20
Criteria for inclusion and research methods.
05:52
Assessment of neurological status and effects of the drug.
07:00
Comparability of groups and analysis features.
07:50
The primary criterion for evaluating effectiveness on the Rankin scale.
10:20
Secondary effectiveness criteria.
10:28
Assessment of the quality of life and the dynamics of changes.
12:36
Reducing the severity of symptoms of depression and cognitive disorders.
13:38
Patient profile and improvement of the quality of life.
14:22
Mexidol® after a stroke - treatment results

Block of articles on this topic

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in acute and early restorations. Periods

Authors:
L.V. STAKHOVSKAYA¹, N.A. SHAMALOV¹, D.R. KHASANOVA², E.V. MELNIKOVA³, A.S. AGAFINA⁴, K.V. GOLIKOV⁵, E.I. BOGDANOV⁶, A.A. YAKUPOVA⁶, L.V. ROSHKOVSKA⁷, L.V. LUKINYKH⁸, T.M. LOKSHTANOVA⁹, I.E. Poverennova¹⁰, L.A. SCHEPANKEVICH¹¹

¹Research Institute of Cerebrovascular Pathology and Stroke, Pirogov Russian National Research Medical University, Moscow, Russia;
²Interregional Clinical and Diagnostic Center, Kazan, Russia;
³St. Petersburg City Hospital No. 26, St. Petersburg, Russia;
⁴St. Petersburg City Hospital No. 40 of the Kurortny Administrative District, St. Petersburg, Russia;
⁵St. Petersburg City Multidisciplinary Hospital No. 2, St. Petersburg, Russia;
⁶Kazan State Medical University, Kazan, Russia;
⁷St. Petersburg Nikolaevskaya Hospital, St. Petersburg, Russia;
⁸Vsevolozhsk Clinical Interdistrict Hospital, Leningrad Region, Russia.
⁹MUBZ City Clinical Hospital No. 1 named after N.I. Pirogov, Samara, Russia;
¹⁰State Budgetary Healthcare Institution Samara Regional Clinical Hospital named after V.D. Seredavin, Samara, Russia;
¹¹Federal State Budgetary Scientific Institution Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.

Review of clinical recommendations for the treatment and prevention of ischemic stroke

Author:
A.I. FEDIN, K.R. BADALYAN

FSBEI in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis

Authors:
I.A. VOZNYUK^1,2, S.V. KOLOMETSEV^2,3, E.M. MOROZOVA¹

Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Effi Cace and Safety of Mexidol in Prolonged Sequential Therapy of Patient S in the Acute and Early Recovery Stages of Hemisphereic Stroke (The Epica Study)

Authors:

LV Stakhovskaya¹, NA Shamalov¹, DR Khasanova², EV Melnikova³, AS Agafina⁴, KV Golikov⁵, EI Bogdanov⁶, AA Yakupova⁶, LV Roshkovskaya⁷, LV Lukinykh⁸, TM Lokshtanova⁹, IE Poverennova¹⁰, LA Shchepankevich¹¹

^1ResearchInstitute of Cerebrovascular Pathology and Stroke, Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
²Interregional Clinical Diagnostic Center, Kazan, Russia.
³St. Petersburg City Clinical Hospital No. 26, St. Petersburg, Russia.
⁴St. Petersburg City Clinical Hospital No. 40 of the Resort Administrative District, St. Petersburg, Russia.
⁵St. Petersburg City General Hospital No. 2, St. Petersburg, Russia.
⁶Kazan Sate Medical University, Russian Ministry of Health, Kazan, Russia.
⁷Nikolaevskaya Hospital, St. Petersburg, Russia.
⁸Vsevolzhsk Clinical Interregional Hospital, Leningradskaya Oblast, Russia.
⁹Pirogov City Clinical Hospital No. 1, Samara, Russia.
¹⁰Seredavin Samara Regional Clinical Hospital, Samara, Russia.
¹¹Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.

Publication place:
NEUROSCIENCE AND BEHAVIORAL PHYSIOLOGY, VOL. 48, NO. 8, OCTOBER, 2018

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com